Amrinone: pharmacokinetics and pharmacodynamics.

Published

Other Article (Review)

Amrinone is a selective inhibitor of phosphodiesterase fraction 3 in both cardiac and smooth muscle. Intravenous administration in humans produces increased contractility and vasodilation of venous capacitance and arterial conductance vessels. The elimination half-life in healthy patients is reported to be 2.6 to 4.1 hours, making it the only long-acting positive inotropic agent available that can be administered either as an intravenous bolus or by infusion. A low incidence of side effects, often minor, has been reported with intravenous use. Thrombocytopenia does not seem to be a problem with short-term use. Amrinone represents a new approach in the pharmacologic therapy for ventricular dysfunction following cardiac surgery.

Full Text

Duke Authors

Cited Authors

  • Levy, JH; Bailey, JM

Published Date

  • December 1989

Published In

Volume / Issue

  • 3 / 6 Suppl 2

Start / End Page

  • 10 - 14

PubMed ID

  • 2521045

Pubmed Central ID

  • 2521045

International Standard Serial Number (ISSN)

  • 0888-6296

Language

  • eng

Conference Location

  • United States